Goldman Sachs Group Inc Inmune Bio, Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 15,304 shares of INMB stock, worth $22,190. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,304
Previous 23,598
35.15%
Holding current value
$22,190
Previous $54,000
42.59%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding INMB
# of Institutions
85Shares Held
5.36MCall Options Held
310KPut Options Held
371K-
Vanguard Group Inc Valley Forge, PA876KShares$1.27 Million0.0% of portfolio
-
Black Rock Inc. New York, NY813KShares$1.18 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$864,73945.87% of portfolio
-
Geode Capital Management, LLC Boston, MA469KShares$680,6880.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$535,6850.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $26M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...